title: Eltrombopag in patients with chronic liver disease.
abstract: BACKGROUND
  Thrombocytopenia may represent a barrier to optimal management of chronic liver disease patients undergoing invasive procedures, or who need to be treated with interferon-based antiviral therapy. Eltrombopag is a thrombopoietic drug that acts upon binding thrombopoietin receptor and stimulates megakaryocytopoiesis and platelet production.
  
  
  METHODS
  A summary of the preclinical studies and of studies carried out in patients with chronic liver disease with eltrombopag are presented in this paper. Data are based on abstracts from journal articles and international conferences found in a PubMed search of literature published up to November 2012.
  
  
  CONCLUSIONS
  Eltrombopag has shown to be capable of reducing the need for platelet transfusion in thrombocytopenic patients with advanced liver disease undergoing invasive procedures and help increase the sustained virological response rate to interferon-based antiviral therapy in patients with chronic hepatitis C who were poor candidates to treatment because of thrombocytopenia. In chronic liver disease patients, the possible benefits of eltrombopag administration should be accurately weighed against the adverse events profile of the drug due to possible concerns regarding the occurrence of thromboembolic events and the potential for decompensation of chronic liver disease.
authors: University of Genoa, Department of Internal Medicine, Gastroenterology Unit, Viale Benedetto XV, No. 6,16132, Genoa, Italy. egiannini@unige.it
authors: Edoardo G
authors: EG
authors: Giannini
authors: Nezam H
authors: NH
authors: Afdhal
mesh_terms: D000818:Animals; D001565:Benzoates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002908:Chronic Disease; D006401:Hematologic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008107:Liver Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011720:Pyrazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists / Q000378:metabolism; D013921:Thrombocytopenia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D034061:Thrombopoiesis / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D001565:Benzoates; D006401:Hematologic Agents; D006834:Hydrazines; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; C520809:eltrombopag